{"entity":{"id":"antibody-oligonucleotide-conjugates","kind":"technology","name":"Antibody-oligonucleotide conjugates","aka":[],"tldr":"An ADC that carries a gene-silencing strand instead of a chemotherapy, so it can switch a protein off rather than poison the cell.","summary":"Conjugating siRNA or antisense oligonucleotides to an antibody is the leading attempt to solve delivery of nucleic-acid drugs beyond the liver. Programmes in muscle disease are furthest along; in oncology the approach would allow tumour-selective silencing of undruggable drivers. Endosomal escape, where only a small fraction of internalised payload reaches the cytosol, is the unsolved problem.","status":"preclinical","asOf":"2026-09-08","links":[{"label":"ClinicalTrials.gov: antibody oligonucleotide conjugate","url":"https://clinicaltrials.gov/search?term=antibody%20oligonucleotide%20conjugate"}],"tags":["frontier","radical"],"related":[],"cancers":[],"sections":["adcs","targeted-therapy"],"technologies":["adc","antisense-sirna","degrader-antibody-conjugate","site-specific-conjugation"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"An internalising antibody delivers a conjugated oligonucleotide into the endosome; a fraction escapes to the cytosol and engages RISC or RNase H.","strengths":["Sequence-programmable payload","Reaches targets with no small-molecule pocket","Builds on mature ADC conjugation chemistry"],"limitations":["Endosomal escape efficiency is very low","No oncology clinical candidate reported","Immunostimulation from oligonucleotide backbones"]},"route":"/technologies/antibody-oligonucleotide-conjugates/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"degrader-antibody-conjugate","kind":"technology","name":"Degrader-antibody conjugate (DAC)","route":"/technologies/degrader-antibody-conjugate/"},{"id":"antisense-sirna","kind":"technology","name":"Oligonucleotide therapeutics","route":"/technologies/antisense-sirna/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"}],"roadmap":[{"id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/"}]}}